PF-03550096

| Cat. No.: | HY-129787 | OH |
|--------------------|---|---------------------------------|
| CAS No.: | 910376-39-5 | |
| Molecular Formula: | C ₁₉ H ₂₈ N ₄ O ₄ | |
| Molecular Weight: | 376.45 | |
| Target: | Cannabinoid Receptor | N |
| Pathway: | GPCR/G Protein; Neuronal Signaling | O ^{NH} NH ₂ |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. | $\overline{\langle}$ |

| BIOLOGICAL ACTIVITY | | |
|---------------------|---|--|
| Description | PF-03550096 is an orally active synthetic cannabinoid (CB) that selectively targets peripheral CB2 receptors with a K _i value of 7.9 nM. PF-03550096 has analgesic activity ^[1] . | |
| IC₅₀ & Target | CB2 7.9 nM (Ki) | |
| In Vivo | PF-03550096 (3, 10 mg/kg, orally, 0.5 h) can inhibit the reduction of colonic pain threshold induced by 2,4, 6-trinitrobenzene sulfonic acid (TNBS) in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

[1]. Kikuchi A, et al. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci. 2008 Feb;106(2):219-24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Product Data Sheet

